Hostname: page-component-f554764f5-rvxtl Total loading time: 0 Render date: 2025-04-10T01:00:25.191Z Has data issue: false hasContentIssue false
  • English
  • Français

In Vivo Assay for Neuroleptic Receptor Binding in the Striatum

Positron Tomography in Humans

Published online by Cambridge University Press:  02 January 2018

H. Cambon ,
J. C. Baron ,
J. P. Boulenger ,
C. Loc'h ,
E. Zarifian  and
B. Maziere
H. Cambon
Affiliation:
Service Hospitalier Frédéric Joliot, Commissariat à l'Energie Atomique
J. C. Baron*
Affiliation:
Service Hospitalier Frédéric Joliot, CEA; Clinique des Maladies du Système nerveux, Hôpital de la Salpétrière, Paris
J. P. Boulenger
Affiliation:
Centre Psychiatrique Esquirol, Caen
C. Loc'h
Affiliation:
Service Hospitalier Frédéric Joliot, CEA
E. Zarifian
Affiliation:
Centre Psychiatrique Esquirol, Caen
B. Maziere
Affiliation:
Service Hospitalier Frédéric Joliot, CEA
*
Service Hospitalier Frédéric Joliot, CEA, Département de Biologie, 91406 Orsay, France
Get access Rights & Permissions [Opens in a new window]

Abstract

Using PET, we investigated the potency in six patients of therapeutic doses of neuroleptic drugs for preventing specific binding of trace doses of intravenously administered 76Br labelled bromospiperone to corpus striatum in vivo. Measured receptor occupancy showed a clear-cut dose-dependent saturation curve with increasing daily oral dose of neuroleptics, indicating the validity and reliability of the method when used as an in vivo radioreceptor assay. Following drug withdrawal in eight patients, recovery to normal or supranormal receptor availability occurred in a matter of days. The results demonstrate an approach that may help resolve controversies about, and design better strategies for, neuroleptic treatment schedules.

Type
Papers
Information
The British Journal of Psychiatry , Volume 151 , Issue 6 , December 1987 , pp. 824 - 830
Copyright
Copyright © Royal College of Psychiatrists, 1987 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

*

Presented in part at the Winter Workshop on Schizophrenia, Schiadming, Austria, 26–31 January 1986, and at the symposium Imagerie Fonctionnelle Cérébrale, Montpellier, France, 6–7 June 1986.

References

Arnett, C. D., Fowler, J. S., Wolf, A. P., Shiue, C. -Y. & McPherson, D. W. (1985), 18F-N-methylspiroperidol: the radioligand of choice for PETT studies of the dopamine receptor in human brain. Life Sciences, 36, 1359–1366.Google Scholar
Baron, J. C., Comar, D., Zarifian, E., Crouzel, C., Mestelan, G., Loo, H. & Acid, Y. (1983) An in vivo study of the dopaminergic receptors in the brain of man using 11C-pimozide and positron emission tomography. In Functional Radionuclide Imaging of the Brain (ed. P. L. Magistretti). New York: Raven Press.Google Scholar
Baron, J. C., Comar, D., Zarifian, E., Crouzel, C., Mestelan, G., Loo, H., Acid, Y., Maziere, B., Loch, C., Cambon, H., Sgouropoulos, P., Bonnet, A. M. & Acid, Y. (1986) Loss of striatal 76Br-bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. Journal of Cerebral Blood Flow and Metabolism, 6, 131–136.Google Scholar
Barone, D., Luzzani, F., Assandri, A., Galliani, G., Mennini, T. & Garattini, S. (1985) In vivo stereospecific 3H-spiperone binding in rat brain: characteristics, regional distribution, kinetics and pharmacological properties. European Journal of Pharmacology, 116, 63–74.Google Scholar
Benes, F. M., Paskevich, P. A., Davidson, J. & Domesick, V. B. (1985) The effects of haloperidol on synaptic patterns in the rat striatum. Brain Research, 329, 265–274.Google Scholar
Byck, R. (1975) Drugs and the treatment of psychiatric disorders. In The Pharmacological Basis of Therapeutics (eds L. S. Goodman & A. Gilman). New York: MacMillan.Google Scholar
Campbell, A., Herschel, M., Cohen, B. M. & Baldessarini, R. J. (1980) Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat. Life Sciences, 27, 633–640.Google Scholar
Campbell, A., Herschel, M., Cohen, B. M., Baldessarini, R. J., Baldessarini, R. J., Teicher, M. H. & Kula, N. S. (1985) Prolonged antidopaminergk actions of single doses of butyro-phenones in the rat. Psychopharmacology, 87, 161–166.Google Scholar
Chugani, D. C., Ackermann, R. F. & Phelps, M. E. (1985) H3-spiperone and F18–2-fluoro-2-deoxyglucose studies of nigro-striatal stimulation in rats. Journal of Cerebral Blood Flow and Metabolism, S (suppl. 1), S161 S162.Google Scholar
Crawley, J. C. W., Smith, T., Veall, N., Zanelli, G. D. Crow, T. J. & Owen, F. (1983) Dopamine receptors displayed in living human brain with 77Br-p-bromospiperone. The Lancet, ii, 975.Google Scholar
Creese, I., Burt, D. R. & Snyder, S. H. (1976) Dopamine receptors and average clinical doses. Science, 194, 546.Google Scholar
Creese, I., Burt, D. R. & Snyder, S. H. (1977) A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature, 270, 180–182.Google Scholar
Crow, T. J., Deakin, J. F. W., Johnstone, E. C. & Longden, A. (1976) Dopamine and schizophrenia. The Lancet, ii, 563–566.Google Scholar
Curry, S. H. (1985) Commentary: the strategy and value of neuroleptic drug monitoring. Journal of Clinical Psychopharmacology, 5, 263–271.Google Scholar
Dahl, S. G. (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Therapeutic Drug Monitoring, 4, 33–40.Google Scholar
Dannies, P. S., Rudnik, M. S., Fishkes, H. & Rudnik, G. (1984) Spiperone: evidence for uptake into secretory granules. Proceedings of the National Academy of Sciences of the USA, 81, 1867–1870.Google Scholar
Davis, J., Janicak, P., Linden, R., Moloney, J. & Pavkovic, I. (1983) Neuroleptics and psychotic disorders. In Neuroleptics: Neurochemical, Behavioral and Cttncal Perspectives (eds J. T. Coyle & S. J. Ena). New York: Raven Press.Google Scholar
Faroe, L., Ehrin, E., Erikson, L., Greitz, T., Hall, H., Hedstrom, C. -G., Litton, J. -E. & Sedvall, G. (1985) Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proceedings of the National Academy of Sciences of the USA, 82, 3863–3867.Google Scholar
Faroe, L., Ehrin, E., Erikson, L., Greitz, T., Hall, H., Hedstrom, C. -G., Litton, J. -E., Sedvall, G., Hall, H., Ehrin, E. & Sedvall, G. (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science, 231, 258–261.Google Scholar
Ferrero, P., Vaccarino, F., Guidotti, A., Costa, E. & Di Chiro, G. (1983) In vivo modulation of brain dopamine recognition sites: a possible model for emission computed tomography studies. Neuropharmacology, 22, 791–795.Google Scholar
Forsman, A. & Ohman, R. (1977) Applied pharmacokinetics of haloperidol in man. current therapeutic research, 21, 396–411.Google Scholar
Gaebel, W. & Pietzcker, A. (1985) Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge: predictors and influence of neuroleptic treatment. European Archives of Psychiatry and Neurological Sciences, 235, 45–52.Google Scholar
Heinrichs, D. W. & Carpenter, W. T. (1985) Experience with a drug-free month in schizophrenic outpatients. Psychopharmacology Bulletin, 21, 117–119.Google Scholar
Hershon, H. I., Kennedy, P. F. & McGuire, R. J. (1972) Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. British Journal of Psychiatry, 120, 41–50.CrossRefGoogle ScholarPubMed
Hogarty, G. E. & Goldberg, S. C. (1973) Drug and sodotherapy in the aftercare of schizophrenic patients: one-year relapse rates. Archives of General Psychiatry, 25, 54–64.Google Scholar
Inoue, Y., Waoner, H. N. Jr, Wong, D. F., Links, J. M., Frost, J. J., Dannals, R. F., Rosenbaum, A. E., Takeda, K., Di Chiro, G. & Kuhar, M. J. (1985) Atlas of dopamine receptor images (PET) of the human brain. Journal of Computer Assisted Tomography, 9, 129–140.CrossRefGoogle ScholarPubMed
Itoh, H., Yagi, G., Tateyama, M., Fujii, Y., Iwamura, K. & Ichikawa, K. (1984) Monitoring of haloperidol serum levels and its clinical significance. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 8, 51–62.Google Scholar
Jenner, P. & Marsden, C. D. (1983) Neuroleptics and tardive dyskinesia. In Neuroleptics: Neurochemical, Behavioral and Clinical Perspectives (eds J. T. Coyle & S. J. Ena). New York: Raven Press.Google Scholar
Korpi, E. R., Kleinman, J. E., Costakos, D. T., Linnoila, M. & Wyatt, R. J. (1984) Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Research, 11, 259–269.Google Scholar
Kuhar, M. J., Murrin, L. C., Malouf, A. T. & Klemm, N. (1978) Dopamine receptor binding in vivo: the feasibility of autoradiographic studies. Life Sciences, 22, 203–210.Google Scholar
Kulmala, H. K., Huang, C. C., Dinerstein, R. J. & Friedman, A. M. (1981). Specific in vivo binding of 77Br-p-bromospiro-peridol in rat brain: a potential tool for gamma ray imaging. Life Sciences, 28, 1911–1916.Google Scholar
Laduron, P. M. (1984) Criteria for receptor sites in binding studies. Biochemical Pharmacology, 33, 833–839.Google Scholar
Laduron, P. M., Janssen, P. F. M. & Leysen, J. E. (1978) Characterization of specific in vivo binding of neuroleptic drugs in rat brain. Life Sciences, 23, 581–586.Google Scholar
Leenders, K. L. Herold, S., Brooks, D. J., Palmer, A. J., Turton, D., Firnau, G., Garnett, E. S., Nahmias, C. & Veall, N. (1984) Pre-synaptic and post-synaptic dopaminergic system in human brain. The Lancet, ii, 110–111.Google Scholar
Leysen, J. E. (1984) Receptors for neuroleptic drugs. In Advances in Human Psychopharmacology, Vol. III (Eds G. D. Burrows & J. S. Werry). Greenwich, Conn.: JAI Press.Google Scholar
Luabeya, M. K., Maloteaux, J. M. & Laduron, P. M. (1984) Regional and cortical laminar distributions of serotonin S2, benzodiazepine, muscarinic, and dopamine D2 receptors in human brain. Journal of Neurochemistry, 43, 1068–1071.Google Scholar
Marsden, C. D., Tarsy, D. & Baldessarini, R. J. (1975) Spontaneous and drug-induced movement disorders in psychotic patients. In Psychiatric Aspects of Neurologic Disease (eds D. F. Benson & D. Blumer). New York: Grune and Stratton.Google Scholar
Martres, M. P., Bouthenet, M. L., Sales, N., Sokoloff, P. & Schwartz, J. C. (1985) Widespread distribution of brain dopamine receptors evidenced with 125I-iodosulpiride, a highly selective ligand. Science, 228, 752–755.Google Scholar
Maziere, B., Loch, C., Hantoaye, P., Guillon, R., Duquesnoy, N., Soussaline, F., Naquet, R., Comar, D. & Maziere, M. (1984) T6Br-bromospiroperidol: a new tool for quantitative in vivo imaging of neuroleptic receptors. Life Sciences, 35, 1349–1356.Google Scholar
Maziere, B., Loch, C., Hantoaye, P., Guillon, R., Duquesnoy, N., Soussaline, F., Naquet, R., Comar, D., Maziere, M., Baron, J. C., Sgouropoulos, P., Duquesnoy, N., D'Antona, R. & Cambon, H. (1985) In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and 76Br-bromospiperone. European Journal of Pharmacology, 114, 267–272.Google Scholar
Meltzer, H. Y., Fang, V. S., Fessler, R., Simonovic, M. & Stanisic, D. (1977) Neuroleptic-stimulated prolactin secretion in the rat as an animal model for biological psychiatry -1. Comparison with anti-psychotic activity. In Animal Models in Psychiatry and Neurology (eds I. Hanin & E. Usdin). New York: Pergamon Press.Google Scholar
Meltzer, H. Y., Fang, V. S., Fessler, R., Simonovic, M., Stanisic, D., Kane, J. M. & Kolakowska, T. (1983) Plasma levels of neuroleptics, prolactin levels, and clinical response. In Neuroleptics: Neurochemical, Behavioral and Clinical Perspectives (eds J. T. Coyle & S. J. Ena). New York: Raven Press.Google Scholar
Nishikawa, T., Tsuda, A., Tanaka, M., Koga, I. & Uchida, Y. (198S) Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry, 20, 1161–1166.Google Scholar
Ohman, R., Larsson, M., Nilsson, I. M. Engel, J. & Carlsson, A. (1977) Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 299, 105–114.CrossRefGoogle ScholarPubMed
Owen, F., Poulter, M., Mashal, R. D., Crow, T. J., Veall, N. & Zanelli, G. D. (1983) 77Br-p-bromospiperone: a ligand for in vivo labelling of dopamine receptors. Life Sciences, 33, 76 S-768.Google Scholar
Peroutka, S. J. & Snyder, S. H. (1980). Relationship of neuroleptic drug effects at brain dopamine, serotonin, -adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry, 137, 1518–1522.Google Scholar
Rivera-Calimum, L. & Hershey, L. (1984) Neuroleptic concentrations and clinical response. Annual Review of Pharmacology and Toxicology, 24, 361–386.CrossRefGoogle Scholar
Robertson, J. S. (1982) Radiation absorbed dose calculations in diagnostic nuclear medicine. International Journal of Applied Radiations and Isotopes, 33, 981–990.Google Scholar
Rom, R. H. (1983) Neuroleptics: functional neurochemistry. In Neuroleptics: Neurochemical, Behavioral and Clinical Perspectives (eds J. T. Coyle A S. J. Ena). New York: Raven Press.Google Scholar
Saelens, J. K., Simke, J. P., Neale, S. E., Weeks, B. J. & Selwyn, M. (1980) Effects of haloperidol and d-amphetamine on in vivo 3H-spiroperidol binding in the rat forebrain. Archives Internationales de Pharmacodynamic, 246, 98–107.Google Scholar
Seeman, P., Lee, T., Chau-Wono, M. & Wono, K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261, 717–719.Google Scholar
Wagner, H. N. Jr. Burns, H. D. Dannals, R. F., Wono, D. F., Lanostrom, B., Duelfer, T., Frost, J. J., Ravert, H. T., Links, J. M., Rosenbloom, S. B., Lukas, S. E., Kramer, A. V. & Kuhar, M. J. (1983) Imaging dopamine receptors in the human brain by positron tomography. Science, 221, 1264–1266.Google Scholar
Wono, D. F., Waoner, H. N. Jr, Dannals, R. F., Links, J. M., Frost, J. J., Ravert, H. T., Wilson, A. A., Rosenbaum, A. E., Gjedoe, A., Douglass, K. H., Petronis, J. D., Folstein, M. F., Toung, J. K. T., Burns, H. D. & Kuhar, M. J. (1984) Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science, 226, 1393–1396.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.